Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort

被引:341
作者
Tagalakis, Vicky [1 ]
Patenaude, Valerie [1 ]
Kahn, Susan R. [1 ]
Suissa, Samy [2 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Clin Epidemiol, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
关键词
Case-fatality; Deep vein thrombosis; Incidence; Mortality; Pulmonary embolism; Venous thromboembolism; DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; RISK-FACTORS; SURGERY; CANCER; MEN; PROPHYLAXIS; DVT; THROMBOPROPHYLAXIS; EPIDEMIOLOGY;
D O I
10.1016/j.amjmed.2013.02.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The public health burden of venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, is not fully known, and contemporary incidence and mortality estimates are needed. We determined the incidence and case fatality of venous thromboembolism in a general population. METHODS: Using the administrative health care databases of the Canadian province of Quebec, we identified all incident cases of deep vein thrombosis or pulmonary embolism between 2000 and 2009 and classified them as definite or probable venous thromboembolism. We formed 2 patient cohorts, one with definite cases and the other including cases with definite or probable venous thromboembolism that were followed until December 31, 2009. RESULTS: We identified 67,354 definite and 35,123 probable cases of venous thromboembolism. The age- and sex-adjusted incidence rates of definite or probable venous thromboembolism, deep vein thrombosis, and pulmonary embolism were 1.22 (95% confidence interval [CI], 1.22-1.23), 0.78 (95% CI, 0.77-0.79), and 0.45 (95% CI, 0.44-0.45) per 1000 person-years, respectively, while for definite venous thromboembolism it was 0.90 (95% CI, 0.89-0.90) per 1000 person-years. The 30-day and 1-year case-fatality rates after definite or probable venous thromboembolism were 10.6% (95% CI, 10.4-10.8) and 23.0% (95% CI, 22.8-23.3), respectively, and were slightly higher among definite cases. The 1-year survival rate was 0.47 (95% CI, 0.46-0.48) for cases with definite or probable venous thromboembolism and cancer, 0.93 (95% CI, 0.93-0.94) for cases with unprovoked venous thromboembolism, and 0.84 (95% CI, 0.83-0.84) for cases with venous thromboembolism secondary to a major risk factor. Similar survival rates were seen for cases with definite venous thromboembolism. CONCLUSION: The risk of venous thromboembolism in the general population remains high, and mortality, especially in cancer patients with venous thromboembolism, is substantial. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:832.e13 / 832.e21
页数:9
相关论文
共 40 条
[1]   Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer [J].
Agnelli, Giancarlo ;
George, Daniel J. ;
Kakkar, Ajay K. ;
Fisher, William ;
Lassen, Michael R. ;
Mismetti, Patrick ;
Mouret, Patrick ;
Chaudhari, Umesh ;
Lawson, Francesca ;
Turpie, Alexander G. G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07) :601-609
[2]   Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study [J].
Agnelli, Giancarlo ;
Gussoni, Gualberto ;
Bianchini, Carlo ;
Verso, Melina ;
Mandala, Mario ;
Cavanna, Luigi ;
Barni, Sandra ;
Labianca, Roberto ;
Buzzi, Franco ;
Scambia, Giovanni ;
Passalacqua, Rodolfo ;
Ricci, Sergio ;
Gasparini, Giampietro ;
Lorusso, Vito ;
Bonizzoni, Erminio ;
Tonato, Maurizio .
LANCET ONCOLOGY, 2009, 10 (10) :943-949
[3]   Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer [J].
Akl, Elie A. ;
Labedi, Nawman ;
Terrenato, Irene ;
Barba, Maddalena ;
Sperati, Francesca ;
Sempos, Elena V. ;
Muti, Paola ;
Cook, Deborah ;
Schuenemann, Holger .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (11)
[4]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[5]   Risk factors for venous thromboembolism [J].
Anderson, FA ;
Spencer, FA .
CIRCULATION, 2003, 107 :I9-I16
[6]   Mortality and recurrence after treatment of VTE: Long term follow-up of patients with good life-expectancy [J].
Andresen, Marianne S. ;
Sandven, Irene ;
Brunborg, Cathrine ;
Njaastad, Anne Mette ;
Strekerud, Finn ;
Abdelnoor, Michael ;
Smith, Pal ;
Abildgaard, Ulrich .
THROMBOSIS RESEARCH, 2011, 127 (06) :540-546
[7]   High risk of recurrent venous thromboembolism in men [J].
Baglin, T ;
Luddington, R ;
Brown, K ;
Baglin, C .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (12) :2152-2155
[8]  
Bergqvist D, 1997, BRIT J SURG, V84, P1099
[9]   Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. [J].
Bergqvist, D ;
Agnelli, G ;
Cohen, AT ;
Eldor, A ;
Nilsson, PE ;
Le Moigne-Amrani, A ;
Dietrich-Neto, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :975-980
[10]  
Canadian Institute for Health Information, 1992, CAN CLASS HLTH INT C